Tharimmune (THAR) said Monday the US Food and Drug Administration has advised that no additional clinical trials are required to support a new drug application for TH104 as a prophylaxis against opioid exposure.
The company said the FDA's feedback is based on existing data on nalmefene, the approved active ingredient embedded in TH104, including its safety profile and efficacy against opioid overdose as well as Tharimmune's pharmacokinetic data to support an "in silico" submission.
Tharimmune said it is seeking to develop TH104 for the additional proposed indication of "temporary prophylaxis of respiratory and/or nervous system depression in military personnel and chemical incident responders entering an area contaminated with high-potency opioids."
The company is developing TH104 for the proposed indication of moderate-to-severe chronic pruritus in patients with primary biliary cholangitis.
Tharimmune shares rose over 5% in recent Monday trading.
Price: 1.44, Change: +0.07, Percent Change: +5.18
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。